Leerink Partnrs Brokers Lower Earnings Estimates for ELAN

Elanco Animal Health Incorporated (NYSE:ELAN) – Equities research analysts at Leerink Partnrs decreased their Q1 2025 EPS estimates for shares of Elanco Animal Health in a research note issued on Tuesday, February 25th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings per share of $0.29 for the quarter, down from their prior forecast of $0.32. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.80 EPS, FY2027 earnings at $1.16 EPS and FY2028 earnings at $1.37 EPS.

Several other equities analysts have also weighed in on the stock. Barclays reduced their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday. Stifel Nicolaus reduced their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Leerink Partners began coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective for the company. Finally, UBS Group reduced their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $15.57.

Elanco Animal Health Stock Up 4.2 %

Elanco Animal Health stock opened at $11.15 on Thursday. Elanco Animal Health has a 52 week low of $10.20 and a 52 week high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company’s 50-day moving average price is $11.74 and its two-hundred day moving average price is $13.06. The stock has a market cap of $5.51 billion, a price-to-earnings ratio of 27.88, a PEG ratio of 2.50 and a beta of 1.42.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.08 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AM Squared Ltd acquired a new stake in shares of Elanco Animal Health during the third quarter worth approximately $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health during the third quarter worth approximately $35,000. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health during the fourth quarter worth approximately $29,000. Farther Finance Advisors LLC boosted its holdings in shares of Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after purchasing an additional 2,044 shares during the period. Finally, Venturi Wealth Management LLC boosted its holdings in shares of Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after purchasing an additional 1,601 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.